Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Algernon Pharmaceuticalsinc (AGN.CN)

Algernon Pharmaceuticalsinc (AGN.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon Announces $1M Private Placement

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon Announces Warrant Extension

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent

AGN.CN : 0.0650 (unch)
AGNPF : 0.0390 (-1.76%)

Barchart Exclusives

Retirement Ready: 3 Dividend Stocks to Set and Forget
These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year after year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar